The melanin concentrating hormone-1 receptor (MCH1R) is a G-protein coupled receptor, expressed in the brain and peripheral tissues that regulates energy storage and body weight. Here we focused on discovery of the mechanism and site of action for a small molecule MCH1R antagonist, which yields weight loss in a mouse model of human obesity. MCH1R is expressed throughout the brain, but also found in peripheral tissues known to regulate fat storage and utilization, e.g. skeletal muscle and adipose tissue. Previous studies of MCH1R antagonist studies have not delineated the site that is critical for mediating the anorexigenic and weight reducing actions. In this study, we evaluated the role of the brain and peripheral tissue receptors.
Introduction
The obesity epidemic continues to increase in many developed and developing countries (Ogden et al., 2003; Haslam and James, 2005) . The 2004 National Health and Nutrition Examination Survey (NHANES) indicated that more than 50% of the US population is either obese or overweight (Hedley et al., 2004; Ogden et al., 2006) . More importantly, the incidence of obese and overweight children is also on the rise. Obesity is associated with multiple metabolic disorders including diabetes and cardiovascular disease (Ogden et al., 2003) . There is a great interest in identifying behavioral and pharmacological approaches to reduce body weight in obese and overweight individuals.
Current weight loss intervention approaches include targets for reducing hunger/appetite, enhancing satiety, increasing metabolism/energy utilization, blocking fat absorption, inhibiting adipose tissue differentiation, and inducing adipose tissue apoptosis. The current therapeutic approaches for weight loss include diet, exercise, and pharmacotherapy. Efficacy is very modest with a high rate of recidivism at the end of the treatment period (Schnee et al., 2006) . Orlistat (Xenical) and sibutramine (Meridia) are currently the only two approved pharmacotherapy agents on the market. Orlistat blocks absorption of fat from the intestine, while sibutramine reduces appetite by acting on brain pathways that regulate hunger (Bray and Ryan, 2007) . These drugs show limited efficacy, and considerable attention is focused on the development of new reagents to decrease body weight. .
Over the past five years the pharmaceutical and biotechnology industry has focused on neural targets that regulate appetite and satiety. Melanin concentrating hormone (MCH) and its receptor the MCH-1 receptor (MCH1R) have emerged as targets for weight reduction (Schwartz and Gelling, 2002) . The MCH1R is a G-protein coupled receptor, which is widely distributed in This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on April 4, 2017 jpet.aspetjournals.org Downloaded from JPET # 130435 6 the brain, however it is also expressed in peripheral organs including adipose tissue and skeletal muscle (Schlumberger et al., 2002) . Hypothalamic MCH and MCH1R expression are increased in states of food deprivation and fasting and rapidly decrease upon refeeding (Qu et al., 1996; Shimada et al., 1998; Ludwig et al., 2001) . Central injections of MCH in rodents lead to an increase in food and water intake (Clegg et al., 2003) and chronic dosing leads to body weight gain (Shearman et al., 2003) , suggesting a critical role of hypothalamic MCH signaling in the regulation of body weight. The converse is true as well, ablation of the MCH and MCH1R gene in both the periphery and brain in mice leads to reduction in body weight and resistance to weight gain on a high fat diet (Shimada et al., 1998; Chen et al., 2002; Marsh et al., 2002) .
These data suggest a role for MCH antagonism as a potential pharmacotherapy in the treatment of obesity (Shimada et al., 1998; Ludwig et al., 2001; Chen et al., 2002; Marsh et al., 2002; Ito et al., 2003) . Functional MCH1Rs are expressed in adipose tissue and MCH stimulates the secretion of leptin from cultured adipocytes. Given that MCH1R is expressed both in peripheral tissues as well as the brain, it is important for the development of pharmacotherapies to determine whether central or peripheral mechanisms are critical for the regulation of food intake, body weight, and energy expenditure.
Here we report utilization of a small molecule medicinal chemistry approach to delineate the site of action of an MCH1R antagonist in the reduction of food intake and body weight. We previously reported the identification of multiple chemical scaffolds that show high affinity toward the receptor Warshakoon et al., 2006) . This study focused on identifying which MCH1R site is critical for mediating the weight-reducing effects. We tested the hypothesis that MCH antagonists need to access the brain MCH1R population to regulate This article has not been copyedited and formatted. The final version may differ from this version. (New Brunswick, NJ).
Chemical Synthesis
Compounds were synthesized in a multiple step sequence starting from commercially available 4-aminoethylbenzoic acid (Scheme 1). The amine was protected with a Boc group.
The corresponding benzoic acid (3) was treated with MeI/NaH followed by DIBAL reduction to give a benzyl alcohol (4). This alcohol was converted to a biaryl amide (5) by removal of the Boc protecting group and then coupling with a biaryl acid sequentially. The formation of a mesylate intermediate (6) followed by displacement with secondary amines furnished the synthesis of requisite amine products 1 and 2, which was obtained after base hydrolysis of methyl ester 7. The final products were purified by a prep-HPLC method to offer 11 weeks prior to the study. Body weights and fat mass were monitored over this period. Upon their initial arrival to the facility the animals were single housed in plastic cages on a reversed light cycle (11:00 a.m. lights off; 11:00 p.m. lights on). This research was conducted in accordance with P&G's policy on research involving animals with strict oversight for care and welfare. All studies were approved by the P&G animal care and use committee.
The mice were randomized into groups (n=8) based on body weight as well as fat composition, which was determined using quantitative magnetic resonance (QMR, EchoMRI, Houston, TX.). The QMR is a validated method for measuring body composition in rodents (Tinsley et al., 2004 ) and we performed our own validation study to confirm its utility in our studies (Sheldon, R.J., Reizes, O., and Cockman, M., unpublished observation). Mice averaging 36 g ± 5, 24 % fat were used in the study. Mice were dosed with compound or vehicle (2 % Tween 80/Saline) via oral (PO) gavage or subcutaneous (SC) administration twice daily for a period of 4 or 10 days. Food intake and body weight were measured daily and body composition was measured at the end of the study. On the last day of dosing, four mice from each dosing group were given a single dose and blood samples from the four mice were then collected approximately 2 hours after dosing to determine peak serum concentrations (Cmax). The blood was put into serum separator tubes, placed on ice for 60 minutes, and centrifuged. The serum was poured off into a tube and frozen until prepared for analysis. Details of analytical analysis are provided in supplemental methods online (Supplemental Methods). Statistical analysis (ANOVA) of measured parameters was performed to determine significance of the compound's effect.
Intracerebroventricle studies in rats
This article has not been copyedited and formatted. The final version may differ from this version. All procedures were performed according to established protocols (Clegg et al., 2003) .
Surgeries were performed at least 7 days after rats arrived in the facility. Rats were anesthetized with 1 ml/kg intraperitoneal injections of a mixture of 70 mg/kg ketamine (Fort Dodge Animal Health, Fort Dodge, IA) and 2 mg/kg xylazine (Lloyd Laboratories, Shenandoah, IA). Rats were placed in a stereotaxic instrument with the skull held horizontally, the sagittal sinus was displaced laterally, and a 21-gauge stainless-steel guide cannula (Plastics One, Roanoke, VA) was lowered directly on the midline, 2.2 mm posterior to bregma, and 7.5 mm ventral to the dura and fixed to the skull with anchor screws and dental acrylic. Obdurators that extended 0.5 mm beyond the cannula tips were inserted. Once the rats regained their pre-operative body weights following surgery, placement of the third ventricle cannulas was confirmed by injection of 10 ng angiotensin II in 1 µl normal saline in water replete rats. Animals that did not drink at least 5 ml of water within 60 minutes were not used.
Conditioned Taste Aversion (CTA) Protocol
The novel tastant was a highly palatable saccharin solution (0.15%). On Day 1, each rat was weighed and assigned into one of 4 weight-matched groups, Saline (0.9 %), Lithium Chloride (10 mg/kg), Vehicle (50 mM Citrate pH 3.5, 2% Tween 80), or MCH antagonist (10 mg/kg)).
Each rat was then water deprived for 23h beginning at 4pm (2h before lights off). On Day 2, bottles of the saccharin solution were weighed and put on each animal's homecage at 3pm (3h 
DABA-821 MCH antagonist shows high affinity towards the MCH1R.
MCH antagonist DABA-821 is a small molecule with MW of 505 (in an HCl salt form) and high affinity for the receptor (Table 1) . DABA-821 bound to the MCH-1R with a K i of 39.3 nM, and was a functional MCH antagonist with an IC 50 of 14.0 nM (Table 1 ). This compound also showed greater than 25 fold selectivity for the MCH1R compared to a structurally related receptor, the serotonin (5HT2c) receptor (Table 1) . DABA-821 is a representative compound of a class of MCH1R antagonists that cause significant body weight and fat mass reduction in rodents.
MCH antagonist reduces body weight and fat mass in mouse DIO model.
Chronic dosing of DABA-821 led to a dose dependent reduction in body weight and fat mass. The antagonist was dosed over a 10 day period twice daily at 1, 3, 10, and 30 mg/kg (Fig.   1 ). DABA-821 showed pronounced weight loss even at a dose of 3 mg/kg compared to vehicle (Fig. 1A) . There was also a reduction in weight from day 0 to day 10 in the vehicle treated mice, likely a result of minor stress due to the handling and dosing. During the 10 days of dosing the 30 mg/kg dosed mice reduced their weight by 7.0 ± 0.5 g of weight or greater than 18 % of their starting body weight. The weight loss was correlated with a dose dependent decrease in cumulative food intake in the mice (Fig. 1B) . At the end of the study, the 30 mg/kg group showed a 37.2 ± 3.9 % reduction in cumulative food intake compared to the vehicle treated mice.
Quantitative Magnetic Resonance (QRR; EchoMRI), was used to determine that the weight loss was due to fat mass decrease and was dose dependent as well, with a maximum reduction in the 30 mg/kg group (Fig. 1C) . The cumulative fat mass reduction was 0.9 ± 0.3 g in the vehicle This 15 treated mice compared with a 5.9 ± 0.3 g reduction in the 30 mg/kg treated mice. In fact, even the 1 mg/kg treated mice showed a reduction of fat, 1.7 ± 0.3 g. There was no apparent reduction in lean mass in any group compared to the vehicle dosed mice (Fig. 1D) . A full necropsy at the end of the dosing period revealed that the reduction in body weight was due solely to adipose tissue mass reduction and not due to reduction in other tissues such as skeletal muscle (data not shown).
Conditioned Taste Aversion (CTA) analysis of DABA-821
We next tested whether administration of the compound would condition an aversion to a novel taste (CTA). As depicted in Figure 2 , animals treated with saline and vehicle consumed significantly more saccharin than water during the 2-hour test. Figure 2 depicts these data as a "preference ratio" (saccharin intake / saccharine + water intake). Values above 50% indicate preference and values below 50% indicate aversion. This test revealed that animals treated with either the positive control (LiCl) or DABA-821 consumed significantly less saccharin than water during the observation period. However, the ratio for DABA-821 was significantly higher than for LiCl-treated rats, indicating a significantly weaker CTA. These data indicate that the compound indeed shows a modest CTA effect though with repeated dosing the food intake effect decreases, yet weight loss continues and reduced weight is maintained throughout the dosing period (Fig. 1b) . The MCH1R antagonist food intake inhibition is greater at the beginning of the 10-day dosing then it is by the end of the dosing. The difference in daily food intake between vehicle and antagonist treated mice was greater at days 1-3 compared to days 6-9.
In vitro analysis of MCH antagonist Carboxy-DABA-822, an amphipathic analog of DABA-821
Having established that this antagonist was an orally potent and efficacious compound in reducing food intake and body weight, we wanted to determine the compounds mode and site of action. It is a widely held assumption that the site of MCH and antagonist action on food intake and body weight must be the hypothalamus though this is based on experiments where MCH is directly injected into the hypothalamus. Using a medicinal approach we tested this hypothesis.
Based on its physical characteristics DABA-821 and related analogs in the literature these compounds are predicted to have widespread tissue distribution.
Carboxy-DABA-822 was synthesized (Scheme 1) to evaluate whether brain accessibility is a necessary part of DABA-821's efficacy. Carboxy-DABA-822 is a structural analog of DABA-821, but has incorporated an amphipathic moiety in order to restrict the compound's access to the brain (Iwasaki et al., 1995) . An additional minor modification was also made which included a biaryl substitution of para-CF 3 in DABA-821 versus para-F biaryls in Carboxy-DABA-822. This modification is not predicted to significantly impact in vivo efficacy based on other analog studies (data not shown). Carboxy-DABA-822 showed similar affinity (K i = 58.5 nM) and antagonism (IC 50 = 35.6 nM) as DABA-821 (Table 1 ). The compound was not evaluated in other selectivity assays.
The ability of the compounds to traverse the blood-brain barrier was assessed using Caco-2 cells. The cells form a circumferential tight junctional cell monolayer similar to the blood-brain epithelium (Borchardt et al., 1996) , thereby providing a good in vitro proxy assay for blood brain barrier permeability (Abbott, 2004) . Both antagonists were assessed experimentally in both the absorptive (i.e. apical to basolateral) and reverse direction (i.e. exsorption) to evaluate the mechanism of transport. DABA-821 showed high passive permeability in the assay (i.e. its absorptive permeability (i.e. 1.1/6.2 x 10 -4 cm/min), indicating that it was a likely substrate for the efflux transporter P-glycoprotein, which is a significant gate-keeper at the blood-brain barrier (Schinkel et al., 1996) . This data suggested that carboxy-DABA-822 would have poor brain penetration. In fact, when the transport of carboxy-DABA-822 was studied in the presence of a P-glycoprotein inhibitor, the absorptive and exsorptive permeabilities normalized as expected (i.e. 1.9/2.1 x 10 -4 cm/min).
In vivo analysis of MCH antagonists
We analyzed the in vivo activity of both MCH antagonists in DIO mice to compare their efficacy. While DABA-821 had been evaluated previously ( Fig. 1) , we reanalyzed the compound. DABA-821 was dosed orally twice daily at 20 mg/kg in DIO mice for a period of 4 days. As expected, compound treated mice showed a reduction in body weight and food intake ( Fig. 3 A and B) . Maximal reduction in body weight after 4 days was 2.6 ± 0.2 g. Cumulative food intake was reduced as well with a 41.2 ± 2.1 % reduction compared to vehicle treated mice.
Body composition analysis using MRR showed a reduction in adipose mass (data not shown).
Similarly, the efficacy of carboxy-DABA-822 was evaluated in DIO mice. The in vitro data indicated that the compound was a functional antagonist but was a substrate for P-glycoprotein in the Caco-2 assay. The compound was dosed orally twice daily at 20 mg/kg and body weight and food intake were monitored ( Fig. 3 C and D) . In contrast to DABA-821, this molecule showed no in vivo activity. Neither food intake nor body weight was changed compared to the vehicledosed groups during the dosing period ( Fig. 3 C and D) .
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Analysis of blood and brain concentrations of antagonists
The Caco-2 cell data indicated that DABA-821 compound should be brain permeable, whereas the carboxy-DABA-822 should be brain impermeable. Indeed, this was confirmed by measuring the brain and serum concentration in oral and subcutaneous dosed DIO mice.
Because the brain levels of dosed compound is ultimately driven by systemic serum levels dosing of compound can be achieved via either oral or subcutaneous route. After 4 days of dosing, mice were dosed a last time with compound and two hours later euthanized, followed by collection of blood and brain for analysis. DABA-821 was orally available with serum concentrations nearing 500 nM (243 ng/ml) after oral administration at 20 mg/kg (Table 2 ). Our studies evaluating the brain concentrations of DABA-821 were performed in subcutaneous dosed mice. We had independently determined that oral or subcutaneous dosing led to significant inhibition of food intake and reduction in body weight, though we observed that subcutaneous dosing led to higher serum levels of the compound (Table 2) . Importantly, as the compound concentration increased so did the efficacy (data not shown). At 7 mg/kg SC, the serum concentration of DABA-821 was ca. 1200 nM (612 ng/ml). Based on the favorable Caco-2 data, the brain concentrations of the compound dosed at 7 mg/kg SC were determined to be 2600 nM (1310 ng/ml). The 20 mg/kg SC dosed mice achieved even greater serum and brain concentrations (Table 2 ) and show dose proportionality. Importantly, regardless of route of administration, the serum and brain concentrations correlated with efficacy of the DABA-821 compound.
We next evaluated the serum and brain concentrations of the putative brain impermeable, carboxy-DABA-822. This compound showed no efficacy yet achieved high serum concentrations, greater than 1500 nM (851 ng/ml), following multiple twice daily oral dosing.
This article has not been copyedited and formatted. The final version may differ from this version. Despite the high serum concentrations, the compound showed very limited brain penetration with concentrations only reaching ca. 20 nM ( Table 2 ). The limited brain presence probably is a reflection of the blood/serum in the brain samples. The brain concentration of this compound was well below the concentration needed to inhibit the receptor (58.5 nM, Table 1 ). The result confirms the CaCO 2 data. Overall, these results suggested that good brain penetration was important for efficacy.
In vivo activity of MCH antagonists directly administered in the brain
While the data above indicated that MCH antagonists needed to penetrate the brain in order to lead to a reduction in food intake and body weight, we confirmed the functional activity of these antagonists further by direct injection into the hypothalamus of rats. To gain accessibility to the hypothalamus, rats were implanted with 3 rd ventricle cannulas and compounds were administered with the appropriate vehicle. Rats were injected with MCH, DABA-821, or both MCH and DABA-821, and food intake was monitored for 1 or 2 hours (Fig.   4A ). MCH stimulated food intake during the observation period, while the DABA-821 alone showed no effect compared to vehicle treated rats. Pretreatment of rats with DABA-821 followed by MCH administration led to a significant inhibition of MCH stimulated food intake (Fig. 5A ). This result supports the hypothesis that this compound exerts its activity via inhibition of the MCH1R in the hypothalamus (Fig. 4A ).
Carboxy-DABA-822 in vivo activity was evaluated via 3 rd ventricle ICV administration as well. The in vitro binding and function data suggested that this compound would be active if it were accessible to the brain MCH1 receptors, so we directly assessed this question. As above, rats were ICV injected with MCH, carboxy-DABA-822, or both MCH and carboxy-DABA-822
This article has not been copyedited and formatted. The final version may differ from this version. Over the past few years, antagonism of the MCH1R has been a popular target for pharmacological treatment of obesity (Vasudevan et al., 2004; Kym et al., 2005; Morens et al., 2005; Palani et al., 2005a; Palani et al., 2005b; Kim et al., 2006; Warshakoon et al., 2006) .
These reports describe various chemical scaffolds with both in vitro and in vivo activity, without definition of where the critical site of action is located. Very simply, these previous studies demonstrated that peripheral administration of small molecule MCH antagonists leads to a reduction in food intake and body weight. Here we present data that indicate a critical feature of the drugs appears to be that they cross the blood brain barrier, demonstrating that brain MCH1R
are critical for body weight regulation.
Our data show that antagonism of the MCH1R leads to a significant reduction in body weight and fat mass (Fig. 1) . These effects appear to be only partially accounted for by reductions in food intake because the weight loss and maintenance of weight loss in the treated mice continues despite a reduced effect on food intake (Fig. 1) . Using pharmacological reagents, we demonstrated for the first time that the site of action of small molecule MCH antagonists is the brain (Fig 3) . In confirmation of these findings, we synthesized a brain impermeable MCH antagonist and showed that this compound is not efficacious with respect to reductions in food intake and body weight even though it was peripherally available (Fig. 3) . When this antagonist is injected directly into the ventricular system, it causes a reduction in food intake ( Fig. 4B ) and body weight (data not shown). Finally our data suggest that brain MCH1Rs, but not peripheral MCH1Rs, are the critical site of action with respect to body weight regulation.
The small molecule MCH antagonist, DABA-821, reduces food intake and body weight. intake in a dose dependent manner (Borowsky et al., 2002; Kowalski et al., 2004; Mashiko et al., 2005) . We found that it inhibits MCH induced food intake when directly injected into the third ventricle with ready access to the hypothalamus (Fig. 4A) . We determined that the compound, dosed orally, crossed the blood brain barrier and that the concentration of the compound in the brain was greater than in the serum. The mechanism underlying the partitioning in the brain is unclear but may be indicative of some type of brain tissue binding of the molecule.
The MCH antagonist DABA-821 induces a modest CTA effect that may account for the reduction in food intake. However, caution must be taken with respect to the interpretation of CTA results. The fact that a substance supports CTA learning is not, in itself, proof of visceral illness nor does it support conclusions about potential drug-regime compliance in humans (Benoit et al., 2003a; Benoit et al., 2003b) . For example, all drugs of abuse including alcohol, morphine, amphetamine and cocaine will cause robust CTAs, even though they are readily selfadministered by rats (Benoit et al., 2003a; Benoit et al., 2003b) . Further, one of the most potent hypothalamic orexigenic neuropeptides, NPY, also produces a robust CTA response (Woods et al., 1998; Madden et al., 1999) . There are several potential interpretations of these data.
However, the important point for our work is that the finding of a significant CTA does not in itself speak to the potential utility for this compound as an effective anti-obesity agent.
To explore the site of action, we synthesized a structural analog of the active MCH antagonist, DABA-822. This molecule was synthesized by placing an amphipathic moiety on the compound, a modification predicted to reduce brain penetration. Indeed, this approach has been used previously to restrict compound access to the brain (Iwasaki et al., 1995) . Our data indicate that adding the carboxylic acid moiety to the compound significantly reduces brain accessibility through P-glycoprotein efflux. Importantly, the changes we made to the compound This article has not been copyedited and formatted. The final version may differ from this version. The medicinal chemistry approach that we took supports a role for the brain MCH1R in the action of MCH antagonists. While it has been speculated that these hypothalamic receptors are the site of action for antagonists in weight loss, there is no experimental evidence to support this hypothesis. The original studies of Borowsky and colleagues showed that peripheral administration of an MCH1R antagonist could inhibit the activity of MCH injected directly into the brain (Borowsky et al., 2002) . The MCH antagonist was found to bind to sites in the brain and hypothalamus, apparently coincident with the sites of MCH1 receptor binding sites. Yet, there is no in vitro or in vivo evidence to support the compound penetrates the brain. Further evidence in support of the hypothesis rely on direct injection of MCH or MCH antagonists into the hypothalamus followed by evaluation of food intake and body weight (Bednarek et al., 2002; Hervieu, 2003; Kennedy et al., 2003; Shearman et al., 2003) . While informative, these data only indicate that the hypothalamus is one site of action for MCH and MCH antagonists, leaving open the role of the peripheral MCH1Rs. Our data helps to more definitively delineate the site of action for the MCH1R antagonists.
These data support a role for MCH in the regulation of body weight. Our studies demonstrate the central nervous system receptors are important in the regulation of body weight.
Furthermore, no in vivo role for the peripheral receptors was demonstrated. Peripheral MCH1
receptors have been shown to stimulate the secretion of leptin from isolated adipocytes and activate adipocyte signaling pathways (Bradley et al., 2000; Bradley et al., 2002) . Because the MCH1R in adipocytes stimulates the secretion of leptin, an MCH antagonist would be predicted to inhibit or suppress leptin secretion. As a consequence of suppressed leptin secretion, food intake would increase. Interestingly, DIO mice treated with carboxy-DABA-822 (restricted to the periphery) showed a small but not significant increase in food intake compared to vehicle treated mice (Fig. 3) . The significance of leptin regulation by peripheral MCH remains unclear, though availability of a peripheral MCH antagonist may be a useful reagent to delineate this function.
Our findings support the concept that the MCH1R is a good target for obesity therapy.
Blockade of the receptor in mouse and rat obesity models lead to significant weight loss. Our studies clearly indicate that brain access is critical for efficacy of small molecule MCH1R
antagonists. The need to get these small molecule antagonists into the brain may be one of the reasons that MCH antagonists have yet to reach clinical studies. Given the importance of finding efficacious pharmacological therapeutics for obesity, it is likely that MCH antagonists will one day be part of the clinical cadre of therapies.
This article has not been copyedited and formatted. The final version may differ from this version. at the end of the study using magnetic resonance relaxometer (Echo MRI). Mice were 8 weeks old when they were placed on high fat diet for a period of 12 weeks prior to start of the study.
Initial body weights of all the groups were 38.5 ± 0.5 g and their fat content was approximately 11.2 ± 0.2 g. n = 8 per group and * p < 0.05. Mean preference ratio (saccharin intake/total fluid intake) after intraperitoneal administration of Saline or LiCl (10mg/kg), or oral gavage of Vehicle or MCH-antagonist (DABA-821, 10 mg/kg).
Data shown are 2 hour fluid intakes. * indicate significant differences by one-way ANOVA (p<0.05). a indicates significant difference between LiCl treated and DABA-821 treated rats (p < 0.05). Holm-Sidak post-hoc test was used to compare the groups (Sigmastat 3.1). Group sizes were saline (n = 8), LiCl (n = 7), Vehicle (n = 6), and DABA-821 (n = 8).
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